Biotechnology
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA ...
2024-05-10 12:16
1005
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- CelltrionUSA announced today that adalimumab-aa...
2024-05-10 07:41
616
Origin Agritech Receives GMO Safety Certificate for its Triple Stack Maize
Commercial Rollout to Begin Shortly BEIJING, May 9, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the issuance of a GMO safety certificate for its transgenic maize, BBL2-2, marking a signif...
2024-05-09 20:30
783
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...
2024-05-09 15:30
860
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...
2024-05-08 21:00
948
TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...
2024-05-08 20:00
681
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting
SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...
2024-05-08 18:18
5258
Andall Biosciences Introduces 23WELL: A Breakthrough New Brand with Ovary Care Capsules (1+1) as its Stellar Debut Product
SHANGHAI, May 8, 2024 /PRNewswire/ -- Andall Biosciences Inc. (ABI), a renowned biotechnology company at the forefront of life science research and applications, has made a significant stride with the introduction of their groundbreaking new product line, 23WELL. The brand takes center stage with...
2024-05-08 18:11
711
FDA Grants Orphan Drug Designation to 9MW2821
SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...
2024-05-07 22:00
758
Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024
Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...
2024-05-07 21:08
875
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
2024-05-07 13:27
1004
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...
2024-05-03 19:00
1942
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
2024-05-02 07:01
1414
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...
2024-05-01 17:14
1085
Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...
2024-04-30 23:00
2030
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...
2024-04-30 20:55
1243
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...
2024-04-30 20:16
1223
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...
2024-04-30 19:00
981
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
* The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. * The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas ...
2024-04-30 10:55
995
CARsgen Submitted Responses to FDA Observations
SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive...
2024-04-29 20:50
848
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 319 media titles]
2024-05-08 14:37
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 318 media titles]
2024-05-07 08:00
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 310 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 297 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
15061
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
10501
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9876
